Una bebida o dos al día podrían ayudar a reducir las probabilidades de muerte de un hombre en las dos décadas tras un ataque cardiaco, sugiere un estudio reciente. La investigación, que aparece en la edición en línea del 28 de marzo de la revista European Heart Journal, incluyó a más de 1,800 hombres estadounidenses que sobrevivieron a un primer ataque cardiaco entre 1986 y 2006, y a quienes se dio seguimiento durante hasta veinte años. En ese periodo, murieron 468 de los hombres.
Builds Upon Existing Alliance and Allows Both Companies to Offer a Comprehensive Cardiovascular Portfolio to U.S. Customers Abbott to Distribute St. Jude Medical FFR Lesion Assessment and OCT Imaging Systems.
Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today it expects total revenues for the fourth quarter of 2011 will be approximately $92.7 million , bringing expected full year 2011 revenues to approximately $343.5 million.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with coronary artery disease. As a result of the positive interim analysis, the FAME II independent Data Safety Monitoring Board (DSMB) has recommended investigators stop patient enrollment in this trial as the DSMB considers it unethical to continue to randomize patients to optimal medical therapy (OMT) alone.
The first fully biodegradable coronary artery stent implanted in humans proved safe in a 10-year study published in Circulation. The paper “Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents” was published online ahead of print on 16 April.
On 23 April, Boston Scientific announced that it has completed enrolment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve implantation (TAVI) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
There is a causal link between increased body mass index (BMI) and the risk for ischemic heart disease, according to a new study.
Pulse oximetry is a fairly accurate way to screen newborns for critical congenital heart defects, a meta-analysis determined.
Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia. TruVue s diagnostic benefits include the ability to: record and wirelessly transmit every heartbeat for up to 30 days; perform advanced arrhythmia analysis; and to provide immediate online access to all transmitted ECG.
Transaortic valve replacement (TAVI) boosts quality of life rapidly with sustained benefits over the mid term, researchers found in real-world practice.
Over time, patients with severe symptomatic aortic stenosis have become more likely to choose transcatheter aortic valve implantation (TAVI) over the gold-standard surgical valve replacement, a French registry showed.
Continuing oral anticoagulation when undergoing implantation of a cardiac device appears to minimize the bleeding risk compared with a heparin bridging strategy, a meta-analysis showed.
Patients with implantable defibrillators (ICDs) or resynchronization devices with defibrillator (CRT-Ds) were most likely to die of heart failure or noncardiac causes, not sudden death, a single-center study found.
Medtronic has announced the initiation of its investigational device exemption (IDE) study for the Abre venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in patients with iliofemoral venous outflow obstruction.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos